BioClinica’s first quarter 2010 earnings were flat compared with the same period 2009, with service revenues of $14.7 million. First quarter revenues last year were $14.5 million. Net income was $711,000, or $0.05 per diluted share, compared with $786,000, or $0.05 per diluted share for Q1 2009.

The company, which acquired clinical trial management software company TranSenda a month ago, reiterated its full-year 2010 service revenue forecast of $61 million to $65 million, but revised its earnings per share estimate to be in the range $0.23 to $0.27 per share (down from $0.25 to $0.29) to account for the financial impact of the TranSenda transaction.